Fetal Fibronectin versus Cervical Length as Predictors of Preterm Birth in Twin Pregnancy with or without 17-Hydroxyprogesterone Caproate

被引:10
|
作者
Combs, C. Andrew [1 ,2 ]
Garite, Thomas J. [1 ,3 ]
Maurel, Kimberly [1 ]
Das, Anita [4 ]
机构
[1] Mednax Inc, Ctr Res Educ & Qual, Sunrise, FL USA
[2] Obstetrix Med Grp, San Jose, CA USA
[3] Univ Calif Irvine, Dept Obstet & Gynecol, Irvine, CA 92717 USA
[4] Axistat Inc, San Francisco, CA USA
关键词
fetal fibronectin; cervical length; twin pregnancy; 17-hydroxyprogesterone caproate; preterm birth prediction; CERVICOVAGINAL FIBRONECTIN; PREMATURE DELIVERY; SYSTEMATIC REVIEWS; RISK-FACTORS; WOMEN; PROGESTERONE; GESTATIONS; BLIND;
D O I
10.1055/s-0034-1370342
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective The objective of this study was to compare cervicovaginal fetal fibronectin (FFN) versus transvaginal sonographic cervical length as predictors of preterm birth in twin pregnancy and to test whether 17-hydroxyprogesterone caproate (170HPc) modifies the predictive value of FFN. Study Design Secondary analysis of a randomized trial of 170HPc versus placebo in dichorionic-diamniotic twins, analyzing the subset with screening FFN (N = 198) and/or cervical length (N = 214) at 24 to 26 weeks of gestation. Results Positive FFN was found in 7%, cervical length <= 25 mm in 8%, and both positive FFN and cervical length <= 25 mm in 3%. Birth <32, <34, and <37 weeks occurred in 8, 30, and 67%, respectively. In logistic regression analysis controlling for FFN, cervical length, prior preterm birth, and treatment group, positive FFN was significantly associated with birth <30 and <32 weeks (odds ratio 55.0 [95% confidence interval 5.2-582], 18.1 [3.3 99], respectively, p < 0.001 for both) but cervical length <= 25 mm was not (odds ratio 0.1 [0.002-1.6], 0.6 [0.1-4.3]). Conclusion Positive FFN was stronger than cervical length <= 25 mm in predicting early preterm birth in twins, regardless of 170HPc use. Treatment with 170H Pc did not appear to alter the predictive value of FFN.
引用
收藏
页码:1023 / 1029
页数:7
相关论文
共 50 条
  • [1] Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17-hydroxyprogesterone caproate
    Combs, C. Andrew
    Garite, Thomas
    Maurel, Kimberly
    Das, Anita
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S205 - S205
  • [2] Use of 17-Hydroxyprogesterone Caproate in Twin Gestations With a Prior Singleton Spontaneous Preterm Birth
    Ward, Andrew R.
    Greenberg, Victoria Rachel
    Valcarcel, Breanna
    Al-Kouatly, Huda Bachir
    Berghella, Vincenzo
    OBSTETRICS AND GYNECOLOGY, 2019, 133 : 221S - 221S
  • [3] The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length
    Romero, Julie
    Rebarber, Andrei
    Saltzman, Daniel H.
    Schwartz, Rachel
    Peress, Danielle
    Fox, Nathan S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (01)
  • [4] Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation
    Megli, Christina
    Combs, C. Andrew
    Venkataramanan, Raman
    Lemon, Lara
    Caritis, Steve N.
    AMERICAN JOURNAL OF PERINATOLOGY, 2022, 39 (11) : 1183 - 1188
  • [5] 17-hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy
    Combs, C. Andrew
    Garite, Thomas J.
    Maurel, Kimberly
    Cebrik, Deborah
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 206 (01) : S213 - S213
  • [6] Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate
    Durnwald, Celeste P.
    Momirova, Valerija
    Rouse, Dwight J.
    Caritis, Steve N.
    Peaceman, Alan M.
    Sciscione, Anthony
    Varner, Michael W.
    Malone, Fergal D.
    Mercer, Brian M.
    Thorp, John M., Jr.
    Sorokin, Yoram
    Carpenter, Marshall W.
    Lo, Julie
    Ramin, Susan M.
    Harper, Margaret
    Spong, Catherine Y.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2010, 23 (12): : 1360 - 1364
  • [7] Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth
    DeNoble, Anna E.
    Wynn, Clara E.
    Weaver, Kristin E.
    Wheeler, Sarahn M.
    Swamy, Geeta K.
    AMERICAN JOURNAL OF PERINATOLOGY, 2020, 37 (03) : 264 - 270
  • [8] Does timing of 17-Hydroxyprogesterone caproate initiation influence risk of preterm birth?
    Carter, Ebony B.
    Macones, George A.
    Stwalley, Dustin
    Olsen, Margaret
    Tuuli, Methodius
    Stout, Molly J.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01) : S96 - S97
  • [9] Clinical Factors Associated with Use of 17-Hydroxyprogesterone Caproate for Prevention of Preterm Birth
    Yee, Lynn M.
    Liu, Lilly Y.
    Sakowicz, Allie
    Bolden, Janelle R.
    Miller, Emily S.
    REPRODUCTIVE SCIENCES, 2016, 23 : 106A - 107A
  • [10] Racial and ethnic disparities in use of 17-hydroxyprogesterone caproate for prevention of preterm birth
    Yee, Lynn M.
    Liu, Lilly Y.
    Sakowicz, Allie
    Bolden, Janelle R.
    Miller, Emily S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : S12 - S13